Background: Clinicians providing dialysis care have numerous erythropoiesis-stimulating agents (ESAs) available for treating anemia. We sought to provide a contemporary description of ESA types used in hemodialysis (HD) settings in nine European countries. Methods: Our study uses Dialysis Outcomes and Practice Patterns Study phase 5 (2012-2015) data from nine European countries
Introduction
Anemia is a common complication seen in patients with end-stage kidney disease on hemodialysis (HD) [1] . During the early years of HD treatment, patients required frequent red blood cell transfusions to maintain target hemoglobin levels. However, in 1989, the first human re-Nephron 2018;140:24-30 DOI: 10.1159/000490202 combinant erythropoiesis-stimulating agent (ESA), epoetin alfa [2] , was introduced commercially and quickly became a key therapeutic agent for treating anemia in maintenance HD patients. Epoetin beta [3] received European marketing authorization in 1990 [4] . Posttranslational modifications to these initial ESAs were developed to provide longer duration of action, such as darbepoetin alfa, introduced worldwide in 2001 [5] , and methoxy polyethylene glycol-epoetin beta (alternatively and henceforth, continuous erythropoietin receptor agonist [CERA] ), introduced in Europe in 2007 [6] . Lastly, biosimilar products -biological medicines highly similar to another already approved biological medicine (the "reference medicine") that are approved according to the same standards of pharmaceutical quality, safety, and efficacy that apply to all biological medicines -have been available in Europe since 2007 [7] , providing additional choices for managing anemia in HD patients. Thus, clinicians providing HD care have a number of options in their ESA arsenal for treating anemia.
Studies reporting on the variety of ESA types used in Europe are scant. We sought to provide a contemporary description of ESA products used in HD settings in 9 European countries and to provide some information on dose conversions used to support achieved hemoglobin levels.
Methods
The Dialysis Outcomes and Practice Patterns Study (DOPPS) is a prospective cohort study of center-based, adult chronic HD patients in > 20 countries ongoing since 1996. Study sites and patients are randomly selected to achieve nationally representative samples in each country. Details on study design and objectives have been published [8] [9] [10] . Our study uses DOPPS phase 5 (2012-2015) data from 9 countries in Europe (Belgium, France, Germany, Italy, Russia, Spain, Sweden, Turkey, and the United Kingdom). Overall, 164 facilities and 3,281 patients contributed cross-sectional data for analysis. The interquartile range (IQR; 25th-75th percentiles) for study entry date was May 2012 through October 2013. Additional data from DOPPS phase 4 (2009-2012) were used for longitudinal analyses as described below. The DOPPS maintains ethics committee approvals in all participating countries, and informed consent was collected from all selected study patients.
Hemoglobin and ESA prescription data, including product type (isoform) and dose, were collected for study patients at DOPPS 5 study entry and monthly thereafter in some countries. Product types captured included short-acting epoetin isoforms (e.g., epoetin alfa, beta, delta, zeta, theta, including biosimilars regulated by the European Medicines Agency [EMA] and other copies not authorized by the EMA), darbepoetin alfa, and CERA. The DOPPS 5 surveys did not distinguish ESA biosimilars and copies from their originator drugs. Thus, our characterization of epoetin alfa includes the originator drug, biosimilars regulated by the EMA (e.g., epoetin zeta), and other copies of epoetin alfa not authorized by the EMA. ESA doses were standardized to a per-week (7 days) value and were based upon prescriptions rather than actual amount administered. Doses for short-acting ESAs were additionally stratified by route of administration (intravenous, subcutaneous). Cross-sectional results are provided using patient level and facility aggregated data.
Among patients in 4 countries (Germany, Italy, Spain, UK) for which monthly longitudinal data were available between January 2011 and April 2015, we estimated dose conversion ratios between short-acting ESAs (IV-administered only), darbepoetin alfa, and CERA. These analyses were restricted to patients prescribed the indicated ESA for at least 3 of the 4 months in the respective preor post-conversion periods. The mean of monthly ESA doses during the 4 months prior to the conversion and the mean of monthly ESA doses for months 3-6 after conversion (thereby allowing for a titration period) were used to establish the conversion ratio for each patient. We report the median within-patient conversion ratio across patients, adjusted for within-patient hemoglobin differences between the pre-vs. post-conversion periods.
Hemoglobin levels were reported for all patients included in these analyses at study entry. Cross-sectional patient hemoglobin values were assigned to the ESA type prescribed for the patient at study entry. Hemoglobin distributions by ESA type were estimated using a kernel density plot with normal (Gaussian) weighting.
Data management and statistical analyses were performed using SAS 9.4 (SAS Institute, Inc., Cary, NC, USA).
Results
The patient level distribution of ESA types by country is shown in Figure 1 . We observed broad variability across countries in overall use of ESA types: use of shortacting types (epoetin alfa or epoetin beta) ranged from 22% (France) to 78% (Russia); use of darbepoetin alfa ranged from 13% (Russia) to 53% (UK); and use of CERA ranged from < 3% (Sweden) to 26% (France). Use of other ESAs (e.g., epoetin theta) was highest in Germany and Russia (4 and 3%, respectively). Intravenous route of administration was 88% for darbepoetin alfa and CERA, 82% for epoetin alfa, and 57% for epoetin beta. Using aggregated longitudinal data available from 6 countries (Belgium, Germany, Italy, Spain, Sweden, and the UK), we observed a trend toward greater use of "other" ESAs (primarily epoetin theta) from 2010 to 2015, driven largely by sharp trends in the distribution of ESA types used in some of the individual countries over this time period (online suppl. proximately 32% (n = 52) of facilities reported use of a single ESA type; of these, 42% reported using darbepoetin alfa, 50% used short-acting types (either epoetin alfa or epoetin beta), and 8% used CERA. Use of 2 ESA types was reported by 40% of facilities (n = 65); of these, the most common combinations were epoetin alfa and darbepoetin alfa (51%) and darbepoetin alfa and CERA (20%). Three ESA types were used by 21% of facilities (n = 34), and 8% of facilities (n = 13) reported using all 4 ESA types. Across facilities, all possible combinations of epoetin alfa, epoetin beta, darbepoetin alfa, and CERA were observed. Figure 3 shows the distribution of dosing frequency by ESA type. Epoetin alfa and epoetin beta were most commonly administered 1-3 times per week (95-97%). For epoetin alfa, median intravenous doses were 8,735 units/week (IQR 5,028-13,914) and 5,572 units/week (IQR 2,998-7,734), when dosed 3x versus 2x per week, respectively. For epoetin beta, when dosed 3x versus 2x per week, median intravenous doses were 9,606 units/ week (IQR 6,000-15,370) and 4,759 units/week (IQR 4,000-7,845), respectively. Darbepoetin alfa was most commonly administered weekly (66%) or biweekly (22%), with median doses of 132 µg/month (IQR 79-228) and 57 µg/month (IQR 37-110), respectively. CERA was most commonly administered monthly (83%) or biweekly (12%), with median doses of 109 µg/month (IQR 62-159) and 150 µg/month (IQR 109-215), respectively. Overall ESA dose distributions by type are presented in Table 1 .
ESA type switching was fairly uncommon among patients followed for at least 6 months, with only 77 conversions identified. The median within-patient conversion ratio between short-acting ESAs and darbepoetin alfa (n = 47) was 206 (iv) epoetin units to 1 µg darbepoetin alfa (IQR 168-321), adjusted for the difference in hemoglobin values before and after conversion for each patient. The median adjusted conversion ratio between short-acting ESA and CERA (n = 21) was slightly higher at 255 (iv) epoetin units to 1 µg CERA (IQR 167-390). The median adjusted conversion ratio between the long-acting ESAs (n = 9) was 0.89 µg CERA to 1 µg darbepoetin (IQR 0.65-1.51).
Distributions of achieved hemoglobin levels by ESA type are shown in Figure 4 . Observed mean and quartile values (25th, median, 75th) were very similar by ESA type: 11.1, 10.4, 11.2, and 11.9 g/dL for darbepoetin alfa; 11.2, 10.5, 11.2, and 11.9 g/dL for CERA; 11.1, 10.3, 11.2, and 12.0 g/dL for epoetin alfa; and 11.1, 10.3, 11.2, and 11.9 g/dL for epoetin beta. No differences in the unadjusted distributions of hemoglobin values by ESA type were detected using Kolmogorov-Smirnov statistics. 
Discussion
In this paper, we described the prevalence of ESA practices in Europe using a cross-sectional sample of HD patients in the DOPPS, finding broad variability in the use of different ESA types within individual facilities and countries with no apparent differences in the unadjusted distribution of achieved hemoglobin levels.
European ESA practice is rather diverse, with many facilities using multiple ESA options. To wit, we observed that nearly 70% of European facilities use more than 1 ESA type, and nearly 30% use 3 or more. Comparative studies of established ESA products have generally been unable to detect substantial differences in efficacy or safety outcomes [11] [12] [13] . The decision to use 1 ESA over another can thus be summarized by several other factors: chiefly cost, availability, and preferences for dosing fre- quency [14] . Since the conversion ratios between epoetin alfa and darbepoetin alfa increase at higher doses [5] , some nephrologists may also prefer to use long-acting ESAs in hyporesponsive patients to avoid excessively high doses of short-acting epoetin alfa. Use of long-acting ESAs also reduces the frequency of administration, which may be important for (1) reducing the plasma peak of ESAs, possibly associated with side effects, (2) limiting the nurses' burden in injecting the patients at the end of HD when they are very busy, and (3) reducing the need for refrigerators to stock larger amounts of ESAs. Additional considerations, such as providing continuity of care for patients during periods of medical transition [15] (e.g., from chronic kidney disease to HD) and location of manufacturing plants, may also influence regional, intrafacility, and inter-country heterogeneity of ESA types.
We observed remarkably similar distributions of achieved hemoglobin levels across ESA types. As this was not a study of ESA efficacy, we did not attempt to adjust hemoglobin levels for ESA dose or use of iron supplementation. However, most clinicians would be "treating to target" with whatever product they have available, in accordance with established recommendations [16] . We acknowledge as a limitation that the DOPPS 5 surveys did not distinguish ESA biosimilars regulated by the EMA, and other copies not authorized by the EMA, from their originator drugs. Several studies of European HD patients have suggested that higher biosimilar ESA doses (as much as 40% higher) may be necessary to maintain similar hemoglobin levels, compared to originator products [17, 18] . However, biosimilars approved by the EMA are required to demonstrate safety and efficacy profiles comparable to the originator biologic drug [19] . Prescribing quotas, tender/reimbursement schemes, and other policy mechanisms to promote the use of biosimilars in Europe vary by country [20, 21] and thus may also influence the availability and relative pricing of certain ESA types as described in our study.
ESA product conversions were very uncommon in our study (< 1% of patients with 6+ months of follow-up). The estimated dose conversion ratios between short-acting ESA types and darbepoetin alfa in our analysis were in line with other experimental and observational studies. Suggested dose conversions between epoetin alfa and darbepoetin alfa vary according to baseline, or pre-conversion, level [5] , and the conversion factor typically is higher at higher baseline dose levels. Our median estimated conversion factor of 206 (iv) epoetin units to 1 µg darbepoetin alfa falls within the range of plausible values previously reported in the literature [22] [23] [24] . Recommended dose conversion ratios for CERA have not been provided by the manufacturer, but a multicenter observational study of HD patients who converted from darbepoetin alfa to CERA estimated a mean dose conversion ratio of 1.21 [25] . Our observed median conversion ratio of 0.89 was based on only 9 observed conversions from darbepoetin alfa to CERA and should not be viewed as authoritative. On the other hand, the lower conversion ratio for CERA is internally consistent with the observational data collected in this study, where monthly CERA dose is approximately 10% lower than for darbepoetin alfa (median, 109 vs. 121 µg/month; mean, 158 vs. 171 µg/month; Table 1 ). Our study did not capture the reasons for within-patient switching of ESA types. However, we speculate that, due to absence of any particular medical indication for doing so, physicians are hesitant to use an alternative ESA once a patient has established tolerance and effectiveness with a given ESA for legal, ethical, or other reasons (i.e., raising risk of immunogenicity). Thus, the mixture of ESAs used within a given facility may, to an extent, reflect the mixture of dialysis vintage (i.e., years on dialysis) and medical status of patients within the facility.
A strength of our study is its use of stratified random sampling of dialysis units within each study country, thereby allowing broad generalizability of study findings within those countries. Although the DOPPS uses a randomized sampling design, the facility sample may not capture all regional variations within a country that could affect the types of ESAs available to clinicians.
In summary, a variety of short-acting (such as epoetin alfa and epoetin beta) and long-acting (such as darbepoetin alfa and CERA) ESAs are commonly used in European HD facilities to treat anemia. Only onethird of facilities in the 9 DOPPS European countries used a single ESA for their patients, whereas 30% of facilities used either 3 or 4 different ESA types for managing anemia within each facility. The availability of these numerous ESA options for managing anemia has allowed European care providers to use the type of ESA best suited for optimizing anemia management according to the particular circumstances of each patient when not greatly limited by local reimbursement policies.
